Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis

Clinical Infectious Diseases

Volumn 49, Issue 11, 2009, Pages 1721-1728

  Sun, Hsin Yun ^a,u   Alexander, Barbara D ^c   Lortholary, Olivier ^v   Dromer, Francoise ^w   Forrest, Graeme N ^d,ab   Lyon, G Marshall ^e   Somani, Jyoti ^e   Gupta, Krishan L ^x   Del Busto, Ramon ^f   Pruett, Timothy L ^h   Sifri, Costi D ^h   Limaye, Ajit P ⁱ   John, George T ^y   Klintmalm, Goran B ^j   Pursell, Kenneth ^k   Stosor, Valentina ^l   Morris, Michelle I ^m   Dowdy, Lorraine A ^m   Munoz, Patricia ^z   Kalil, Andre C ^o   Garcia Diaz, Julia ^p   Orloff, Susan ^q   House, Andrew A ^aa   Houston, Sally ⁿ   Wray, Dannah ^r   Huprikar, Shirish ^s   Johnson, Leonard B ^g   Humar, Atul ^q,ab   Razonable, Raymund R ^t   Husain, Shahid ^b,ac   Singh, Nina ^a   more..

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

^f HENRY FORD HOSPITAL   (United States)

^g St John Medical Center   (United States)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY OF CHICAGO   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁿ TAMPA GENERAL HOSPITAL   (United States)

^o UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^p OCHSNER CLINIC FOUNDATION   (United States)

^q OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^r MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^s MOUNT SINAI MEDICAL CENTER   (United States)

^t MAYO CLINIC   (United States)

^u NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^v HÔPITAL NECKER ENFANTS MALADES   (France)

^w INSTITUT PASTEUR   (France)

^x POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^y CHRISTIAN MEDICAL COLLEGE   (India)

^z HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^aa UNIVERSITY OF WESTERN ONTARIO   (Canada)

^ab TORONTO GENERAL HOSPITAL   (Canada)

^ac UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CYCLOSPORIN A; FLUCYTOSINE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID CULTURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FUNGEMIA; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 72849130455     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/647948     Document Type: Article

References (36)

1. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18:44-69.
2. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16:677-688
3. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients: report of 9 cases and review of the literature. Medicine (Baltimore) 1996; 75:142-156 (Pubitemid 26159211) (Pubitemid 26159211)
4. Fortun J, Martin-Davila P, Moreno S, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52:813-819 (Pubitemid 37407810) (Pubitemid 37407810)
5. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001; 71:910-913 (Pubitemid 32417353)
6. Sun HY, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis 2009; 48:1566-1576
7. Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008; 47:1321-1327
8. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7:375-381
9. Singh N, Lortholary O, Dromer F, et al. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation 2008; 86:647-651
10. Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756-764 (Pubitemid 46273051) (Pubitemid 46273051)
11. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142-1151
12. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14. (Pubitemid 33152659) (Pubitemid 33152659)
13. Lortholary O, Poizat G, Zeller V, et al. Long-term outcome of AIDSassociated cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006; 20:2183-2191 (Pubitemid 44684709) (Pubitemid 44684709)
14. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007; 4:e21.
15. Singh N, Lortholary O, Alexander BD, et al. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation 2005; 80:1033-1039 (Pubitemid 41611924) (Pubitemid 41611924)
16. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:710-718 (Pubitemid 30736975) (Pubitemid 30736975)
17. Perfect JR et al. Clinical practice guidelines for the management of cryptococcal disease: 2009 update by the Infectious Disease Society of America. Clin Infect Dis 2009 (in press).
18. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22:315-321 (Pubitemid 26056161)
19. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11:1463-1471 (Pubitemid 27421177)
20. Astellas Pharma US I. Treatment of cryptococcal meningitis in HIVinfected patients (study 94-0-013). Available at: http://www.ambisome.com/index2.php? sectionpabout&pageptrials. Accessed 8 March 2009.
21. Hamill R, Sobel J, El-Sadr W, Johnson P, Graybill JR. Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients [abstract 1161]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). 1999.
22. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O.Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE 2008; 3:e2870.
23. Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25:1295-1320 (Pubitemid 36677281) (Pubitemid 36677281)
24. Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect 2008; 14(Suppl 4):25-36.
25. Takemoto K, Yamamoto Y, Ueda Y. Influence of the progression of cryptococcal meningitis on brain penetration and efficacy ofAmBisome in a murine model. Chemotherapy 2006; 52:271-278 (Pubitemid 44608661) (Pubitemid 44608661)
26. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 2008; 47:226-235
27. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusionrelated toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995; 38:459-465 (Pubitemid 26042075)
28. Simitsopoulou M, Roilides E, Dotis J, et al. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother 2005; 49: 1397-1403 (Pubitemid 40463368) (Pubitemid 40463368)
29. Sau K, Mambula SS, Latz E, Henneke P, Golenbock DT, Levitz SM. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem 2003; 278:37561-37568 (Pubitemid 37175278) (Pubitemid 37175278)
30. Bellocchio S, Gaziano R, Bozza S, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Tolllike receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother 2005; 55:214-222 (Pubitemid 40331148) (Pubitemid 40331148)
31. Devine DV, Wong K, Serrano K, Chonn A, Cullis PR. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta 1994; 1191:43-51. (Pubitemid 24133527) (Pubitemid 24133527)
32. Eierman DF, Yagami M, Erme SM, et al. Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia. Proc Natl Acad Sci U S A 1995; 92: 2815-2819
33. Lewis RE, Chamilos G, Prince RA, Kontoyiannis DP. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob Agents Chemother 2007; 51:1078-1081 (Pubitemid 46355298) (Pubitemid 46355298)
34. Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 2003; 1:17-24.
35. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337:15-21.
36. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764-1767 (Pubitemid 38698379) (Pubitemid 38698379)